255 related articles for article (PubMed ID: 23717429)
1. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring.
Kim H; Kim K; Yu SJ; Jang ES; Yu J; Cho G; Yoon JH; Kim Y
PLoS One; 2013; 8(5):e63468. PubMed ID: 23717429
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
[TBL] [Abstract][Full Text] [Related]
3. Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma.
Zhang A; Yin C; Wang Z; Zhang Y; Zhao Y; Li A; Sun H; Lin D; Li N
J Int Med Res; 2016 Dec; 44(6):1414-1423. PubMed ID: 27885040
[TBL] [Abstract][Full Text] [Related]
4. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
[TBL] [Abstract][Full Text] [Related]
5. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.
Yan D; He Q; Chen Y; Wang L; Zhang X
J Clin Lab Anal; 2011; 25(2):113-7. PubMed ID: 21438004
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma.
Qi Y; Xu F; Chen L; Li Y; Xu Z; Zhang Y; Wei W; Su N; Zhang T; Fan F; Wang X; Qin X; Zhang L; Liu Y; Xu P
Oncotarget; 2016 Oct; 7(42):68242-68252. PubMed ID: 27626164
[TBL] [Abstract][Full Text] [Related]
7. Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study.
Wang K; Bai Y; Chen S; Huang J; Yuan J; Chen W; Yao P; Miao X; Wang Y; Liang Y; Zhang X; He M; Yang H; Guo H; Wei S
Cancer Med; 2018 Jun; 7(6):2691-2698. PubMed ID: 29696820
[TBL] [Abstract][Full Text] [Related]
8. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.
Sun Y; Gao G; Cai J; Wang Y; Qu X; He L; Liu F; Zhang Y; Lin K; Ma S; Yang X; Qian X; Zhao X
Carcinogenesis; 2013 Mar; 34(3):595-604. PubMed ID: 23188673
[TBL] [Abstract][Full Text] [Related]
9. Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma.
Kim H; Sohn A; Yeo I; Yu SJ; Yoon JH; Kim Y
Clin Chem; 2018 Aug; 64(8):1230-1238. PubMed ID: 29875214
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the role of interleukin-6 in diagnosis of hepatocellular carcinoma.
El-Folly RF; El-Kabarity RH; Arafa NA
Egypt J Immunol; 2010; 17(2):11-22. PubMed ID: 23082483
[TBL] [Abstract][Full Text] [Related]
11. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
13. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma.
Ahn YH; Shin PM; Oh NR; Park GW; Kim H; Yoo JS
J Proteomics; 2012 Sep; 75(17):5507-15. PubMed ID: 22789673
[TBL] [Abstract][Full Text] [Related]
14. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
15. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.
Zekri AN; Youssef AS; El-Desouky ED; Ahmed OS; Lotfy MM; Nassar AA; Bahnassey AA
Tumour Biol; 2016 Sep; 37(9):12273-12286. PubMed ID: 27271989
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein.
Meng Z; Ren Q; Zhong G; Li S; Chen Y; Wu W; Feng Y; Mao M; Zhang F; Long G
J Mol Diagn; 2021 Sep; 23(9):1174-1184. PubMed ID: 34182124
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
19. Five Novel Oncogenic Signatures Could Be Utilized as AFP-Related Diagnostic Biomarkers for Hepatocellular Carcinoma Based on Next-Generation Sequencing.
Yu Z; Wang R; Chen F; Wang J; Huang X
Dig Dis Sci; 2018 Apr; 63(4):945-957. PubMed ID: 29442275
[TBL] [Abstract][Full Text] [Related]
20. Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west African populations.
Fye HK; Wright-Drakesmith C; Kramer HB; Camey S; Nogueira da Costa A; Jeng A; Bah A; Kirk GD; Sharif MI; Ladep NG; Okeke E; Hainaut P; Taylor-Robinson SD; Kessler BM; Mendy ME
PLoS One; 2013; 8(7):e68381. PubMed ID: 23935864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
